additional information

来源: ClearCase 于 2025-10-21 15:25:05 [] [博客] [旧帖] [给我悄悄话] 阅读数 : (1592 bytes)

In fact, the survival improvements in the current study were most pronounced in patients with tumors that were not likely to respond well to immunotherapy because of low production of PD-L1. These patients experienced a nearly five-fold improvement in three-year overall survival rates with receipt of a COVID vaccine, researchers reported at the 2025 European Society for Medical Oncology Congress in Berlin.

请您先登陆，再发跟帖！